Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab
Ji Hoon Kim, Ji Won Han, Hee Sun Cho, Jeong Won Jang, Kwon Yong Tak, Pil Soo Sung · 2025
Read Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab by Ji Hoon Kim, Ji Won Han, Hee Sun Cho, Jeong Won Jang, Kwon Yong Tak, Pil Soo Sung (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12731153.txt.
Description
Ji Hoon Kim and his five co-authors, publishing in 2025, test whether a tumor protein predicts how liver cancer patients fare on a standard drug pairing. The protein, glypican-3, appears in most liver tumors but not in healthy adult liver. The team reviewed 139 patients with advanced disease treated at one center with the two-drug combination, and stained their tumors for the protein.
Patients whose tumors carried the protein died sooner. The link survived adjustment for other factors, with risk of death about 1.8 times higher. Their tumors also shrank less often under treatment, about 17 percent responding against 32 percent. Time without the disease worsening, however, did not differ clearly. Where the protein sat in the cell mattered too: membrane placement was worst. The authors suggest the stain could help sort patients by risk before treatment.
Catalog record
| CREATOR | Ji Hoon Kim, Ji Won Han, Hee Sun Cho, Jeong Won Jang, Kwon Yong Tak, Pil Soo Sung |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |